Interferon Beta
Links shared publicly online about this topic
Medications for MS: What--™s the difference between interferon beta-1a and interferon beta-1b? - Multiple Sclerosis
healthcentral.com — “Four of the seven currently available disease-modifying MS drugs are often referred to as “the interferons” - Avonex, Rebif, Betaseron, and Extavia....” View full resource at healthcentral.com
Most Recently Shared on December 1, 2010 at 4:36 pm By:
Medications for MS: What's the difference between interferon beta-1a and interferon beta-1b? http://ow.ly/1afB1E
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients - Drugs.com MedNews
drugs.com — “- One-Year Phase II Data Presented at the 2010 ACTRIMS Meeting Sanofi-aventis (EURONEXT SAN and NYSE SNY) reported today new one-year data from a Phase II study” View full resource at drugs.com
Most Recently Shared on June 7, 2010 at 6:50 pm By:
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients: PARIS,... http://bit.ly/c1x7WK
Add-On Daclizumab Treatment May Be Better In Reducing Multiple Sclerosis Disease Activity Than Interferon Beta Alone
medicalnewstoday.com — “An article published Online First and in the April edition of The Lancet Neurology reports that add-on daclizumab treatment might reduce multiple sclerosis disease activity more than standa” View full resource at medicalnewstoday.com
Most Recently Shared on February 16, 2010 at 1:08 pm By:
Add-On Daclizumab Treatment May Be Better In Reducing Multiple Sclerosis Disease Activity Than Interferon Beta Alone http://mnt.to/3xG5
Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). ” View full resource at medicalnewstoday.com
Most Recently Shared on July 9, 2009 at 5:14 pm By:
MedNewsToday: Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a.. http://twurl.nl/vwqmdp
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
fda.gov — “Novartis Pharmaceuticals Corporation (Novartis) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. The recall has been initiated due to concerns about potential microbial contamination of the alcohol products with Bacillus cereus, that could potentially lead to life-threatening infections.” View full resource at fda.gov
Most Recently Shared on January 31, 2011 at 11:37 pm By:
Important Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products http://bit.ly/h9WgT4
BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a)
medicalnewstoday.com — “The European Medicines Agency has been formally notified by BioPartners GmbH of its decision to withdraw its application for Biferonex (interferon beta-1a), 6 million-international-unit solution f” View full resource at medicalnewstoday.com
Most Recently Shared on May 31, 2009 at 10:23 am By:
MedNewsToday: BioPartners GmbH Withdraws Its Application For Biferonex (interferon Beta-1a): The Eu.. http://tinyurl.com/mk2dbg
Setbacks In Patients With Relapsing-Remitting Multiple Sclerosis Can Be Reduced If Methylprednisolone Is Added To Interferon Beta
medicalnewstoday.com — “Conclusions reported in an Article published Online first, as well as in the June edition of The Lancet Neurology, and the announcement made at the American Academy of Neurology meeting in ” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2009 at 12:04 pm By:
MedNewsToday: Setbacks In Patients With Relapsing-Remitting Multiple Sclerosis Can Be Reduced If Me.. http://tinyurl.com/c8ccfk
Anais Brasileiros de Dermatologia - Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis
scielo.br — “Anais Brasileiros de Dermatologia - Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis” View full resource at scielo.br
Most Recently Shared on May 22, 2011 at 3:19 pm By:
Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis: Esclerose múlti... http://bit.ly/m37Xj0
PolygenicBlog: Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients.
polygenicpathways.blogspot.com — “Concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, Autism, Bipolar disorder , multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue” View full resource at polygenicpathways.blogspot.com
Most Recently Shared on April 27, 2011 at 11:26 am By:
http://www.linkedin.com/pub/chris-carter/22/560/76a" /> Dr Chris Carter Doctor, Medical Technology, Pharmacist, and PhD
Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. http://goo.gl/fb/K81kg
Important Information for Extavia (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
usrecallnews.com — “Some of these alcohol prep pads from Triad may have been included in U.S. packaging for Extavia, a product marketed by Novartis. The Triad alcohol prep pads should not be used.” View full resource at usrecallnews.com
Most Recently Shared on February 2, 2011 at 3:25 am By:
Important Information for Extavia (interferon beta 1-b) Patients Regarding Triad Group’s Alcohol Prep Products http://f.ast.ly/Xhexq
Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate
content.karger.com — “No abstract available” View full resource at content.karger.com
Most Recently Shared on March 31, 2011 at 4:03 am By:
Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and G... http://bit.ly/hT9bUe
Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
businesswire.com — “Press Release Content” View full resource at businesswire.com
Most Recently Shared on October 22, 2011 at 1:27 pm By:
Alemtuzumab Significantly Reduces Relapses in #MS versus Interferon Beta-1a in a Phase 3 Study #ECTRIMS2011 http://t.co/7iVePsGM
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study : The Lancet Neurology
thelancet.com — “Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. By - Dr Bhupendra Khatri MD, Frederik Barkhof MD, Giancar...” View full resource at thelancet.com
Most Recently Shared on May 21, 2011 at 3:12 am By:
[Articles] Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomi... http://bit.ly/lLRSIf
Medical News: AAN: Cancer Risk Low with Interferon Beta-1a for MS - in Meeting Coverage, AAN from MedPage Today
medpagetoday.com — “TORONTO -- Data from controlled clinical trials and postmarketing surveillance indicate that multiple sclerosis patients treated with subcutaneous interferon Beta-1a (Rebif) do not have an increased r” View full resource at medpagetoday.com
Most Recently Shared on April 15, 2010 at 3:37 pm By:
AAN: Cancer Risk Low with Interferon Beta-1a for MS (CME/CE) TORONTO (MedPage Today) -- Data from controlled clinical t.. http://dld.bz/at6s
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients - News Press Release | PharmiWeb.com
pharmiweb.com — “- One-Year Phase II Data Presented at the 2010 ACTRIMS MeetingPR NewswirePARIS, June 5, 2010PARIS, June 5, 2010 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) reported today new one-year data from a Phase II study with teriflunomide, a” View full resource at pharmiweb.com
Most Recently Shared on June 7, 2010 at 12:52 pm By:
Press Release: PARIS, June 5, 2010 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) reported today new... http://bit.ly/apPTtX
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Lisa Emrich
Patient Advocate and Blogger, Living with Multiple Sclerosis and Rheumatoid Arthritis, Musician, Educator, and writer for HealthCentral.com
-
OrganizedWisdom MS
Organizing multiple sclerosis resources shared by health experts, advocates, and organizations into WisdomCards.
-
MNT Health News
Featured health news published by Medical News Today and chosen by the editorial team.
Advertisement
